Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nektar Therapeutics - Common Stock (NQ:NKTR)

30.90 +6.45 (+26.38%)
Streaming Delayed Price Updated: 10:33 AM EDT, Jun 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nektar Therapeutics - Common Stock

< Previous 1 2 3 4 5 6 Next >
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Nektar Therapeutics Announces Positive Data From Eczema Drug In Mid-stage Trial: Stock More Than Doubles But Retail Sees It Rising Further
Nektar Therapeutics said its mid-stage trial showed that patients who received Rezpegaldesleukin demonstrated improvement in eczema area and severity score compared to placebo at week 16. 
Via Stocktwits
Topics Economy Government
Crude Oil Falls Sharply; US Current Account Deficit Widens In Q1
Via Benzinga
Earnings Scheduled For May 8, 2025
Via Benzinga
Nektar Therapeutics's Earnings: A Preview
Via Benzinga
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Looking for insights into the US markets in the middle of the day on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
Which stocks are gapping on Tuesday?
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
Nasdaq Surges 1%; TD Synnex Posts Upbeat Earnings
Via Benzinga
Nektar Therapeutics Shares Double On Promising Eczema Drug Data
Nektar reported positive Phase 2b trial data for rezpegaldesleukin in atopic dermatitis, showing strong efficacy and a consistent safety profile. 
Via Benzinga
Nektar Therapeutics Launches By Triple Digits On Eczema Grand Slam
The company's experimental eczema drug met all the primary and secondary goals in a midstage study. 
Via Investor's Business Daily
Tuesday's pre-market session: top gainers and losers
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why Nektar Therapeutics Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket
Via Benzinga
US Stocks Likely To Open Higher After Trump Announces Iran-Israel Ceasefire: FedEx, TD Synnex In Focus Ahead Of Earnings
U.S. futures were trading higher on Tuesday after a positive day of trade on Monday. Futures of major benchmark indices were trading higher. 
Via Benzinga
Topics Government
Nektar Therapeutics Stock Rallies Sharply After-Hours With Major Skin Drug Results Just Hours Away
Rezpegaldesleukin is being studied not only in atopic dermatitis but also in alopecia areata, with topline data from the second trial expected in December. 
Via Stocktwits
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Top movers in Monday's after hours session
After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
Assessing Nektar Therapeutics: Insights From 5 Financial Analysts
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Assessing Nektar Therapeutics: Insights From 4 Financial Analysts
Via Benzinga
Earnings Scheduled For March 12, 2025
Via Benzinga
Top movers in Friday's after hours session
As the regular session of the US market concludes on Friday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
This Levi Strauss Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential
Piper Sandler initiates coverage of Nektar Therapeutics, citing REZPEG's Treg-focused action as a potential breakthrough for Alopecia areata treatment. 
Via Benzinga
10 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
NKTR Stock Earnings: Nektar Therapeutics Misses EPS, Beats Revenue for Q2 2024
NKTR stock results show that Nektar Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
NKTR Stock Earnings: Nektar Therapeutics Meets EPS, Beats Revenue for Q1 2024
NKTR stock results show that Nektar Therapeutics met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.